QurAlis

Qur Alis

Biotechnology, 700 Main St, Cambridge, Massachusetts, 02139, United States, 51-200 Employees

quralis.com

  • twitter
  • LinkedIn

phone no Phone Number: 78********

Who is QURALIS

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effec...

Read More

map
  • 700 Main St, Cambridge, Massachusetts, 02139, United States Headquarters: 700 Main St, Cambridge, Massachusetts, 02139, United States
  • 2016 Date Founded: 2016
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from QURALIS

QurAlis Org Chart and Mapping

Employees

Rakhee Ganti

Sr. Manager, Regulatory Affairs and Medical Writing

Bryan Boggs

Vice President Regulatory Affairs

Samantha Rubino

Associate Director Clinical Operations

Ethan Ripps

Global Supply Chain Co-Op

Taylor Gray

Senior Program Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding QurAlis

Answer: QurAlis's headquarters are located at 700 Main St, Cambridge, Massachusetts, 02139, United States

Answer: QurAlis's phone number is 78********

Answer: QurAlis's official website is https://quralis.com

Answer: QurAlis's revenue is $10 Million to $25 Million

Answer: QurAlis's SIC: 2834

Answer: QurAlis's NAICS: 325412

Answer: QurAlis has 51-200 employees

Answer: QurAlis is in Biotechnology

Answer: QurAlis contact info: Phone number: 78******** Website: https://quralis.com

Answer: At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access